article thumbnail

Riverain Technologies Launches New FDA-Cleared Technology, Expands Globally

DAIC

4, 2025 Riverain Technologies recently announced it expanded across eight countries in 2024 and added nearly 50 new customers with its ClearRead solutions to clearly, confidently and quickly detect cardiothoracic diseases. tim.hodson Tue, 02/04/2025 - 16:21 Feb.4,

article thumbnail

How Echo IQ Transforms Heart Disease Diagnosis with Cutting-Edge AI

Cassling

What does the future of heart disease detection look like? Strange dives into how EchoSolv leverages cutting-edge technology to tackle one of cardiology's most challenging conditions. EchoSolv, the groundbreaking AI platform developed by Echo IQ, is revolutionizing the detection of aortic stenosis. In this video, Prof.

article thumbnail

Breakthrough is a game changer in heart valve technology

Science Daily - Heart Disease

When a patient needs a new heart valve, the current mechanical and tissue replacements each have strengths and weaknesses. Now, a team of researchers believe they have found a way to harness the strengths of both technologies in a way that could be life-changing -- and life-saving -- for many.

article thumbnail

Baptist Health Lexington Enhances 20-Year Leadership in Pioneering Advanced Robotic Technology for Heart Disease Patients

DAIC

The robotic technology represented an entirely novel way to address heart rhythm disorders in a minimally invasive procedure with the benefits of robotic precision and safety. This new technology, invested in by Baptist Health Lexington, along with the expertise of their staff; will continue to help so many Kentuckians just like me.

article thumbnail

Cleerly Receives FDA Breakthrough Device Designation for Heart Disease Risk Staging System

DAIC

milla1cf Wed, 03/06/2024 - 18:48 March 6, 2024 — Cleerly , the company on a mission to create a new standard of care to aid in the diagnosis of heart disease, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration ( FDA ) for its Coronary Artery Disease ( CAD ) Staging System.

article thumbnail

Landmark Clinical Study in The Lancet Finds New AI Technology Can Predict Cardiac Events Due to Coronary Inflammation at Least 10 Years in Advance

DAIC

Caristo Diagnostics Limited has announced the results of a landmark clinical study published in The Lancet that support the ability of Caristo's CaRi-Heart AI technology to quantify coronary artery inflammation and accurately predict cardiac events. The CaRi-Heart technology is in clinical use in the UK, European Union, and Australia.

article thumbnail

Over 630,000 ECG data used to develop AI tool for early diagnosis of heart disease in Japan

Mobi Health News - ECG

Clinical research is set to verify the technology's effectiveness in estimating abnormal heart movements.